Jacques Galipeau

List of Publications by Year in Descending Order

229 papers	11,226 citations	54 h-index	101 g-index
271 ext. papers	12,743 ext. citations	5.4 avg, IF	6.76 L-index

#	Paper	IF	Citations
229	X-linked genes exhibit miR6891-5p-regulated skewing in Sjögren's syndrome.. *Journal of Molecular Medicine*, **2022**, 1	5.5	1
228	Aryl hydrocarbon receptor in mesenchymal stromal cells: new frontiers in AhR biology. *FEBS Journal*, **2021**, 288, 3962-3972	5.7	3
227	Role of Virus-Specific T Cell Therapy for Cytomegalovirus and BK Infections in Kidney Transplant Recipients.. *Kidney360*, **2021**, 2, 905-915	1.8	0
226	Unique molecular characteristics and microglial origin of Kv1.3 channel-positive brain myeloid cells in Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	6
225	Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. *Cytotherapy*, **2021**, 23, 368-372	4.8	8
224	Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells. *Transplantation and Cellular Therapy*, **2021**, 27, 389.e1-389.e10		1
223	Consensus International Council for Commonality in Blood Banking Automation-International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. *Cytotherapy*, **2021**, 23, 1060-1063	4.8	3
222	Dichotomic Potency of IFNγ Licensed Allogeneic Mesenchymal Stromal Cells in Animal Models of Acute Radiation Syndrome and Graft Host Disease. *Frontiers in Immunology*, **2021**, 12, 708950	8.4	3
221	Minor salivary gland mesenchymal stromal cells derived from patients with Sjögren's syndrome deploy intact immune plasticity. *Cytotherapy*, **2021**, 23, 301-310	4.8	1
220	Washed Equine Platelet Extract as an Anti-Inflammatory Biologic Pharmaceutical. *Tissue Engineering - Part A*, **2021**, 27, 582-592	3.9	1
219	Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity. *Stem Cells*, **2021**, 39, 1145-1154	5.8	13
218	Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match. *Blood Advances*, **2020**, 4, 1987-1997	7.8	32
217	Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination. *Journal of Neuroscience*, **2020**, 40, 5105-5115	6.6	14
216	Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential. *Cytotherapy*, **2020**, 22, 602-605	4.8	23
215	Mesenchymal Stromal Cells for Graft-versus-Host Disease: A Trilogy. *Biology of Blood and Marrow Transplantation*, **2020**, 26, e89-e91	4.7	13
214	CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10+ Tissue Macrophages to Mitigate Gut Injury. *Cell Reports*, **2020**, 30, 1923-1934.e4	10.6	44
213	Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at U.S. academic centers. *Cytotherapy*, **2019**, 21, 782-792	4.8	34

212	Potency Analysis of Mesenchymal Stromal Cells Using a Phospho-STAT Matrix Loop Analytical Approach. *Stem Cells*, **2019**, 37, 1119-1125	5.8	11
211	Molecular Genetic and Immune Functional Responses Distinguish Bone Marrow Mesenchymal Stromal Cells from Hepatic Stellate Cells. *Stem Cells*, **2019**, 37, 1075-1082	5.8	12
210	Image-Guided Transarterial Directed Delivery of Human Mesenchymal Stem Cells for Targeted Gastrointestinal Therapies in a Swine Model. *Journal of Vascular and Interventional Radiology*, **2019**, 30, 1128-1134.e5	2.4	1
209	Challenges for mesenchymal stromal cell therapies. *Science Translational Medicine*, **2019**, 11,	17.5	83
208	Mesenchymal Stem Cells: From Bench to Bedside and Back. *Advances and Controversies in Hematopoietic Transplantation and Cell Therapy*, **2019**, 219-242	0	
207	Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. *Cell Reports*, **2018**, 22, 2504-2517	10.6	91
206	Adoptive transfer of IL-10 regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model. *Cellular and Molecular Immunology*, **2018**, 15, 727-730	15.4	9
205	Extracellular vesicles from bone marrow-derived mesenchymal stromal cells support survival of human antibody secreting cells. *Journal of Extracellular Vesicles*, **2018**, 7, 1463778	16.4	19
204	Mesenchymal Stromal Cells **2018**, 1559-1567		0
203	Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells. *Stem Cell Research and Therapy*, **2018**, 9, 75	8.3	17
202	Reversible secretome and signaling defects in diabetic mesenchymal stem cells from peripheral arterial disease patients. *Journal of Vascular Surgery*, **2018**, 68, 137S-151S.e2	3.5	5
201	Innate immune responses of equine monocytes cultured in equine platelet lysate. *Veterinary Immunology and Immunopathology*, **2018**, 195, 65-71	2	6
200	Autologous Mesenchymal Stromal Cells Prevent Transfusion-elicited Sensitization and Upregulate Transitional and Regulatory B Cells. *Transplantation Direct*, **2018**, 4, e387	2.3	3
199	Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion. *Nature Communications*, **2018**, 9, 3698	17.4	53
198	Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. *Cell Stem Cell*, **2018** , 22, 824-833	18	735
197	Bone Marrow-Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 736-745	4.7	11
196	GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration. *Molecular Therapy*, **2017**, 25, 416-426	11.7	2
195	Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: Lessons from the acute graft versus host disease experience. *Cytotherapy*, **2017**, 19, 655-667	4.8	9

194	Protective role of Indoleamine 2,3 dioxygenase in Respiratory Syncytial Virus associated immune response in airway epithelial cells. *Virology*, **2017**, 512, 144-150	3.6	4
193	Reply: "Function of Cryopreserved Mesenchymal Stromal Cells With and Without Interferon- Prelicensing Is Context Dependent". *Stem Cells*, **2017**, 35, 1440-1441	5.8	4
192	Cell-based therapeutic strategies for multiple sclerosis. *Brain*, **2017**, 140, 2776-2796	11.2	102
191	Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFN priming. *Blood Advances*, **2017**, 1, 628-643	7.8	26
190	The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells. *Oncotarget*, **2017**, 8, 91914-91927	3.3	20
189	The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease - a phase 1 trial with three doses. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 471-81	6.1	70
188	Regulatory B Cells Induce Formation of IL-10-Expressing T Cells in Mice with Autoimmune Neuroinflammation. *Journal of Neuroscience*, **2016**, 36, 12598-12610	6.6	33
187	A novel platelet lysate hydrogel for endothelial cell and mesenchymal stem cell-directed neovascularization. *Acta Biomaterialia*, **2016**, 36, 86-98	10.8	51
186	International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. *Cytotherapy*, **2016**, 18, 151-9	4.8	278
185	A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States. *Blood*, **2016**, 128, 1622-1622	2.2	1
184	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. *Oncotarget*, **2016**, 7, 27753-63	3.3	15
183	A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States. *Blood*, **2016**, 128, 2793-2793	2.2	1
182	Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFN Licensing. *Stem Cells*, **2016**, 34, 2429-42	5.8	94
181	Mesenchymal stromal cells for the treatment of autoimmune diseases **2016**, 794-813		
180	GIFT4 fusokine converts leukemic B cells into immune helper cells. *Journal of Translational Medicine* , **2016**, 14, 106	8.5	7
179	Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGF Neutralizing Fusion Protein. *Cancer Research*, **2016**, 76, 5683-5695	10.1	9
178	Human mesenchymal stromal cells suppress T-cell proliferation independent of heme oxygenase-1. *Cytotherapy*, **2015**, 17, 382-91	4.8	9
177	Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. *Circulation Research*, **2015**, 117, 645-54	15.7	93

176	Mesenchymal Stromal Cells Derived From Crohn's Patients Deploy Indoleamine 2,3-dioxygenase-mediated Immune Suppression, Independent of Autophagy. *Molecular Therapy*, **2015**, 23, 1248-1261	11.7	37
175	Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders. *Stem Cells Translational Medicine*, **2015**, 4, 66-73	6.9	14
174	Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs. *Scientific Reports*, **2015**, 5, 11856	4.9	17
173	Marrow mesenchymal stromal cells derived from subjects with Crohn Disease deploy IDO mediated immune suppression, independent of autophagy process. *Cytotherapy*, **2015**, 17, S43	4.8	
172	Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation. *BMC Immunology*, **2015**, 16, 74	3.7	7
171	Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients. *Journal of Multiple Sclerosis*, **2015**, 2,		16
170	A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency. *Clinical and Translational Immunology*, **2015**, 4, e37	6.8	2
169	Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 934-40	4.7	25
168	The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. *Cytotherapy*, **2015**, 17, 125-7	4.8	55
167	Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA. *Blood*, **2015**, 126, 3779-3779	2.2	3
166	Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease. *World Journal of Gastroenterology*, **2015**, 21, 4779-87	5.6	33
165	Activation of NK and CD8+ T-Cells with a Novel IL-15 and TGF-Beta Receptor Fusion Protein Confers Anti-Tumor Immunity. *Blood*, **2015**, 126, 3421-3421	2.2	
164	IDO-independent suppression of T cell effector function by IFN-licensed human mesenchymal stromal cells. *Journal of Immunology*, **2014**, 192, 1491-501	5.3	177
163	Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2. *EMBO Molecular Medicine*, **2014**, 6, 1476-92	12	73
162	Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. *Stem Cell Reports*, **2014**, 3, 60-72	8	82
161	Maltose-binding protein fusion allows for high level bacterial expression and purification of bioactive mammalian cytokine derivatives. *PLoS ONE*, **2014**, 9, e106724	3.7	10
160	B cells for cancer immunotherapy. *OncoImmunology*, **2014**, 3, e955702	7.2	5
159	Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response. *Cancer Research*, **2014**, 74, 4133-44	10.1	16

158	Tryptophan Catabolites Directly Modulate the Immunosuppressive Effects of MSCs Via Activation of the Endogenous Aryl Hydrocarbon Receptor. *Blood*, **2014**, 124, 1593-1593	2.2	1
157	Tissue engineering of rat bladder using marrow-derived mesenchymal stem cells and bladder acellular matrix. *PLoS ONE*, **2014**, 9, e111966	3.7	34
156	Defining mesenchymal stromal cells responsiveness to IFN^|^gamma; as a surrogate measure of suppressive potency. *Inflammation and Regeneration*, **2014**, 34, 168-175	10.9	1
155	Molecular and Endocrine Mechanisms Underlying the Stem Cell Theory of Aging. *Pancreatic Islet Biology*, **2014**, 389-417	0.4	
154	The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy. *Biomaterials*, **2013**, 34, 7840-50	15.6	58
153	MSCs: science and trials. *Nature Medicine*, **2013**, 19, 812	50.5	38
152	Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy. *American Heart Journal*, **2013**, 165, 558-66	4.9	37
151	Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. *Cytotherapy*, **2013**, 15, 1054-61	4.8	285
150	The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. *Cytotherapy*, **2013**, 15, 2-8	4.8	312
149	From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases. *BioMed Research International*, **2013**, 2013, 929842	3	7
148	Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. *Cancer*, **2013**, 119, 3784-7	6.4	25
147	A fusion cytokine coupling GMCSF to IL9 induces heterologous receptor clustering and STAT1 hyperactivation through JAK2 promiscuity. *PLoS ONE*, **2013**, 8, e69405	3.7	11
146	Properties of immature myeloid progenitors with nitric-oxide-dependent immunosuppressive activity isolated from bone marrow of tumor-free mice. *PLoS ONE*, **2013**, 8, e64837	3.7	7
145	Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. *Current Molecular Medicine*, **2013**, 13, 856-67	2.5	120
144	Immunological Characterization Of Multipotent Mesenchymal Stromal Cells. The International Society For Cellular Therapy (ISCT) Working Proposal. *Blood*, **2013**, 122, 5438-5438	2.2	
143	The immune plasticity of mesenchymal stromal cells from mice and men: concordances and discrepancies. *Frontiers in Bioscience - Scholar*, **2012**, 4, 824-37	2.4	17
142	IFN-□and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. *Blood*, **2012**, 119, 1075-85	2.2	67
141	200 BONE MARROW MESENCHYMAL STROMAL CELL THERAPY FOR RESTORATION OF BLADDER WALL DEFECTS. *Journal of Urology*, **2012**, 187,	2.5	1

140	Adoptive transfer of mesenchymal stromal cells accelerates intestinal epithelium recovery of irradiated mice in an interleukin-6-dependent manner. *Cytotherapy*, **2012**, 14, 1164-70	4.8	20
139	Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. *Cell Stem Cell*, **2012**, 10, 9-10; author reply 10-1	18	78
138	Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-licensing. *Cytotherapy*, **2012**, 14, 147-52	4.8	237
137	New insights on translational development of mesenchymal stromal cells for suppressor therapy. *Journal of Cellular Physiology*, **2012**, 227, 3535-8	7	27
136	Reprogramming of B cells into regulatory cells with engineered fusokines. *Infectious Disorders - Drug Targets*, **2012**, 12, 248-54	1.1	9
135	B effector cells activated by a chimeric protein consisting of IL-2 and the ectodomain of TGF- receptor II induce potent antitumor immunity. *Cancer Research*, **2012**, 72, 1210-20	10.1	12
134	Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. *Molecular Therapy*, **2012**, 20, 187-95	11.7	452
133	Inducible IL10(+) suppressor B cells inhibit CNS inflammation and T helper 17 polarization. *Molecular Therapy*, **2012**, 20, 1767-77	11.7	6
132	FIST, a sword and shield fusokine for cancer immunotherapy. *OncoImmunology*, **2012**, 1, 224-226	7.2	5
131	Peripheral Regulatory B Cell Phenotype in Multiple Sclerosis Patients. *Blood*, **2012**, 120, 4843-4843	2.2	1
130	The immune plasticity of mesenchymal stromal cells from mice and men concordances and discrepancies. *Frontiers in Bioscience - Elite*, **2012**, E4, 824-837	1.6	10
129	Mesenchymal Stem Cells and Tissue Repair **2012**, 35-51		3
128	IFNLicensed Human Bone Marrow Derived Mesenchymal Stromal Cells Inhibit T Cell Cytokine Production by a Mechanism Independent of Indoleamine 2 3-Dioxygenase (IDO) Activity. *Blood*, **2012**, 120, 1255-1255	2.2	
127	GM-CSF and IL-4 Derived Fusion Cytokine Reprograms Leukemic B-Cells to Anti-CLL Effectors. *Blood* , **2012**, 120, 4606-4606	2.2	
126	A Novel Synthetic GMCSF and IL7 Fusion Cytokine (GIFT7) Leads to T Cell Neogenesis by Reversing Age-Related Thymic Atrophy and Overcoming PD-1-Assocaited CD8 Exhaustion. *Blood*, **2012**, 120, 3289-3289	2.2	
125	A GM-CSF and IL-4 Fusion Cytokine Triggers Conversion of B-Cells to Tumoricidal Effectors. *Blood*, **2012**, 120, 1048-1048	2.2	
124	Interleukin-2 enhances angiogenesis and preserves cardiac function following myocardial infarction. *Cytokine*, **2011**, 56, 732-8	4	21
123	Roles of FGF signaling in stem cell self-renewal, senescence and aging. *Aging*, **2011**, 3, 920-33	5.6	87

122	A novel and simplified method of culture of human blood-derived early endothelial progenitor cells for the treatment of ischemic vascular disease. *Cell Transplantation*, **2011**, 20, 1431-43	4	7
121	Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells. *Blood*, **2011**, 117, 6801-12	2.2	100
120	GMCSF-interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer. *Journal of Internal Medicine*, **2011**, 269, 74-84	10.8	14
119	Death and inflammation following somatic cell transplantation. *Seminars in Immunopathology*, **2011**, 33, 535-50	12	41
118	A MCP1 fusokine with CCR2-specific tumoricidal activity. *Molecular Cancer*, **2011**, 10, 121	42.1	16
117	Bone marrow mesenchymal stromal cell therapy for external urethral sphincter restoration in a rat model of stress urinary incontinence. *Neurourology and Urodynamics*, **2011**, 30, 447-55	2.3	58
116	Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B. *Biomaterials*, **2011**, 32, 295-305	15.6	33
115	Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. *Journal of Immunology*, **2011**, 186, 6933-44	5.3	22
114	Development and function of innate polyclonal TCRalphabeta+ CD8+ thymocytes. *Journal of Immunology*, **2011**, 187, 3133-44	5.3	17
113	GM-CSF-based fusion cytokines as ligands for immune modulation. *Journal of Immunology*, **2011**, 186, 5527-32	5.3	18
112	Mesenchymal Stromal Cells: An Emerging Cell-Based Pharmaceutical **2011**, 127-148		
111	A CCL2-based fusokine as a novel biopharmaceutical for the treatment of CCR2-driven autoimmune diseases. *Critical Reviews in Immunology*, **2010**, 30, 449-61	1.8	6
110	Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming. *Cancer Research*, **2010**, 70, 7742-7	10.1	16
109	A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity. *Journal of Immunology*, **2010**, 185, 7358-66	5.3	14
108	Induction of cardiac angiogenesis requires killer cell lectin-like receptor 1 and 47 integrin expression by NK cells. *Journal of Immunology*, **2010**, 185, 7014-25	5.3	29
107	A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. *Molecular Therapy*, **2010**, 18, 1293-301	11.7	23
106	Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. *American Heart Journal*, **2010**, 159, 354-60	4.9	70
105	Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction. *Cell Transplantation*, **2010**, 19, 369-86	4	26

104	Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. *Annals of Neurology*, **2010**, 68, 540-5	9.4	60
103	IDO Expression In Human Mesenchymal Stromal Cells Mediates T Cell Suppression and Leads to Monocyte Differentiation Into IL-10 Secreting Immunosuppressive CD206+ M2 Macrophages. *Blood* , **2010**, 116, 2784-2784	2.2	3
102	A Novel Synthetic GMCSF and MCP3 Fusion Cytokine Induces IL10-Producing B Cells with Immune Modulatory Properties on Antigen Presentation and Th17 Development. *Blood*, **2010**, 116, 587-587	2.2	
101	Interleukin-2 Enhances Angiogenesis and Preserves Cardiac Function Following Myocardial infarction. *Blood*, **2010**, 116, 2786-2786	2.2	
100	A Novel Dendritic Cell Population Generated by Fusing Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-21 Induces Tumor-Antigen Specific Immunity. *Blood*, **2010**, 116, 5177-5177	2.2	
99	Mesenchymal Stromal Cells Accelerate Hematopoietic Reconstitution and Mediate An IL6-Dependent Regeneration of the Intestinal Epithelium of Lethally Irradiated Mice.. *Blood*, **2010**, 116, 3846-3846	2.2	
98	Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review. *Canadian Journal of Gastroenterology & Hepatology*, **2009**, 23, 625-31		16
97	Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. *Journal of Immunology*, **2009**, 182, 7963-73	5.3	226
96	Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 180, 1131-42	10.2	360
95	Selective inhibition of CCR2 expressing lymphomyeloid cells in experimental autoimmune encephalomyelitis by a GM-CSF-MCP1 fusokine. *Journal of Immunology*, **2009**, 182, 2620-7	5.3	14
94	Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. *Molecular Therapy*, **2009**, 17, 369-72	11.7	31
93	Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. *Molecular Therapy*, **2009**, 17, 1799-803	11.7	108
92	Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases. *Molecular Therapy*, **2009**, 17, 1241-9	11.7	25
91	The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation. *Cancer Research*, **2009**, 69, 9020-8	10.1	18
90	Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. *Blood*, **2009**, 114, 2632-8	2.2	117
89	An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis. *Journal of Immunology*, **2009**, 183, 1759-66	5.3	31
88	Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation. *Experimental Hematology*, **2009**, 37, 416-20	3.1	14
87	Three-dimensional porous scaffolds at the crossroads of tissue engineering and cell-based gene therapy. *Journal of Cellular Biochemistry*, **2009**, 108, 537-46	4.7	51

86	The stem cell research environment: a patchwork of patchworks. *Stem Cell Reviews and Reports*, **2009**, 5, 82-8	6.4	34
85	A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. *Nature Medicine*, **2009**, 15, 1038-45	50.5	110
84	Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition. *Stem Cells*, **2009**, 27, 467-77	5.8	51
83	Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?. *Molecular Genetics and Metabolism*, **2009**, 96, 73-6	3.7	4
82	Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1alpha: Targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells. *Stem Cells*, **2009**, 27, 489-97	5.8	36
81	Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. *Journal of Immunology*, **2009**, 182, 5994-6002	5.3	297
80	Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. *Blood*, **2009**, 114, 3181-90	2.2	76
79	Catalyzing umbilical cord blood research in Canada: a survey of current needs and practices of principal investigators. *Journal of Obstetrics and Gynaecology Canada*, **2009**, 31, 63-71	1.3	4
78	Immune-Modulatory Effects of Mesenchymal Stromal Cell Infusions for the Treatment of Factor VIII Inhibitor in Hemophilia A.. *Blood*, **2009**, 114, 1299-1299	2.2	
77	Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. *Oncogene*, **2008**, 27, 208-17	9.2	16
76	The carboxylation efficiency of the vitamin K-dependent clotting factors: studies with factor IX. *Haemophilia*, **2008**, 14, 1063-8	3.3	18
75	CD34 expression on murine marrow-derived mesenchymal stromal cells: impact on neovascularization. *Experimental Hematology*, **2008**, 36, 93-103	3.1	43
74	Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells. *Journal of Biological Chemistry*, **2008**, 283, 17991-8001	5.4	126
73	Design and Fabrication of 3D Porous Scaffolds to Facilitate Cell-Based Gene Therapy. *Tissue Engineering - Part A*, **2008**, 14, 1037-1048	3.9	32
72	Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. *Cardiovascular Research*, **2008**, 79, 405-15	9.9	43
71	Mesenchymal stromal cells genetically engineered to overexpress IGF-I enhance cell-based gene therapy of renal failure-induced anemia. *American Journal of Physiology - Renal Physiology*, **2008**, 295, F488-96	4.3	24
70	Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. *Cancer Research*, **2008**, 68, 4810-8	10.1	62
69	Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. *Blood*, **2008**, 112, 4991-8	2.2	174

68	TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. *Cancer Immunology, Immunotherapy*, **2008**, 57, 1197-206	7.4	21
67	Tetra- and hexavalent mannosides inhibit the pro-apoptotic, antiproliferative and cell surface clustering effects of concanavalin-A: impact on MT1-MMP functions in marrow-derived mesenchymal stromal cells. *Glycobiology*, **2008**, 18, 195-204	5.8	28
66	Design and fabrication of 3D porous scaffolds to facilitate cell-based gene therapy. *Tissue Engineering - Part A*, **2008**, 14, 1037-48	3.9	10
65	Galectin 3-binding protein is a potential contaminant of recombinantly produced factor IX. *Haemophilia*, **2007**, 13, 701-6	3.3	5
64	Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. *Stem Cells*, **2007**, 25, 2660-9	5.8	77
63	Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton. *FASEB Journal*, **2007**, 21, 3928-36	0.9	30
62	Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways. *Molecular Cancer Therapeutics*, **2007**, 6, 441-9	6.1	19
61	Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. *Journal of Immunology*, **2007**, 179, 1549-58	5.3	174
60	MT1-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells: a molecular link between pro-MMP-2 activation, chemotaxis, and cell survival. *Journal of Biological Chemistry*, **2007**, 282, 8142-9	5.4	28
59	A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex. *Blood*, **2007**, 109, 2234-42	2.2	23
58	Stem cell research ethics: consensus statement on emerging issues. *Journal of Obstetrics and Gynaecology Canada*, **2007**, 29, 843-8	1.3	16
57	Genomic, Proteomic and Functional Screens Identify PAI-1 as an Important Factor Influencing Mesenchymal Stromal Cell Survival Post-Transplantation In Vivo.. *Blood*, **2007**, 110, 180-180	2.2	1
56	IFN-g-Stimulated Mesenchymal Stromal Cells Acquire the Ability To Cross-Present Exogenous Soluble Antigens and Lead to an Effective Immune Response.. *Blood*, **2007**, 110, 4898-4898	2.2	
55	Mesenchymal Stromal Cells Genetically Engineered To Overexpress Insulin-Like Growth Factor-1 Provide Paracrine Support for Cell-Based Erythropoietin Therapy of Chronic Renal Failure-Induced Anemia.. *Blood*, **2007**, 110, 2598-2598	2.2	
54	Erythropoietin (Epo) Secreting Mesenchymal Stromal Cells and Autocrine Signalling Via the Epo Receptor. A Novel, Cell-Based Paracrine Epo Delivery System for Cardiovascular Therapy.. *Blood*, **2007**, 110, 1198-1198	2.2	
53	Periostin Is a Previously Uncharacterised Vitamin K Dependent Carboxyglutamic Acid (Gla) Containing Protein Expressed by Marrow-Derived Mesenchymal Stromal Cells.. *Blood*, **2007**, 110, 1927-1927	2.2	
52	Mesenchymal Stromal Cells Gene-Enhanced To Express Human Factor IX and Their In Vivo Use for Correction of Hemophilia B Phenotype in R333Q Mice.. *Blood*, **2007**, 110, 5136-5136	2.2	
51	Immunostimulatory Properties of the Human Ortholog of the GMCSF/IL2 Fusion Protein for Cell Based Therapy.. *Blood*, **2007**, 110, 4894-4894	2.2	

50	Regulation of TLR Expression and Activation in Human Mesenchymal Stromal Cells by IFN-a, IFN-g and TNF-a.. *Blood*, **2007**, 110, 1790-1790	2.2	
49	Mesenchymal Stromal Cells Engineered To Express IL-12 for Breast Cancer Cellular Immunotherapy.. *Blood*, **2007**, 110, 5142-5142	2.2	
48	Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 1576-84	12.7	58
47	A self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression in genetically engineered T-cells. *Virology Journal*, **2006**, 3, 97	6.1	3
46	Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectors. *Virology Journal*, **2006**, 3, 27	6.1	12
45	Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy. *Cell Communication and Adhesion*, **2006**, 13, 79-92		25
44	Cooperation of matrix metalloproteinases with the RhoA/Rho kinase and mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase signaling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells. *Stem Cells*, **2006**, 24, 2557-65	5.8	71
43	Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. *Blood*, **2006**, 107, 2570-7	2.2	272
42	Ex Vivo Gene Therapy for Haemophilia A: FVIII-Overexpressing Mesenchymal Stromal Cells Fail To Produce Sustained Therapeutic Levels of Circulating FVIII In Vivo.. *Blood*, **2006**, 108, 5472-5472	2.2	
41	A GMCSF & IL15 Fusokine Leads to Paradoxical Immunosuppression In Vivo Via Asymmetrical JAK/STAT Signalling through the IL15 Receptor Complex.. *Blood*, **2006**, 108, 3187-3187	2.2	
40	Galectin-3 Binding Protein Contaminates the Purification of Recombinant Factor IX.. *Blood*, **2006**, 108, 1038-1038	2.2	
39	Ex Vivo Gene Trasfer for Hemophilia A That Enhances Safety and Results in Sustained In Vivo Factor VIII Expression from Lentivirally-Engineered Endothelial Progenitors.. *Blood*, **2006**, 108, 3251-3251	2.2	
38	Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. *Cancer Research*, **2005**, 65, 8359-65	10.1	39
37	Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. *Blood*, **2005**, 106, 4057-65	2.2	450
36	Purified Peritoneal Macrophages Do Not Promote Angiogenesis In Vivo.. *Blood*, **2005**, 106, 2665-2665	2.2	
35	Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. *Cancer Research*, **2004**, 64, 3380-5	10.1	55
34	Human-compatible collagen matrix for prolonged and reversible systemic delivery of erythropoietin in mice from gene-modified marrow stromal cells. *Molecular Therapy*, **2004**, 10, 741-8	11.7	29
33	Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. *Cancer Research*, **2004**, 64, 8795-9	10.1	41

32	Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. *Human Gene Therapy*, **2004**, 15, 597-608	4.8	87
31	Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. *Journal of Cellular Biochemistry*, **2004**, 91, 1146-58	4.7	89
30	Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. *Stem Cells*, **2003**, 21, 337-47	5.8	251
29	Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. *Experimental Hematology*, **2003**, 31, 640-9	3.1	61
28	A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. *Gene Therapy*, **2003**, 10, 478-89	4	50
27	Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. *Gene Therapy*, **2003**, 10, 621-9	4	183
26	Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. *Annals of Thoracic Surgery*, **2003**, 75, 204-9	2.7	158
25	The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells. *Journal of Steroid Biochemistry and Molecular Biology*, **2003**, 86, 1-14	5.1	33
24	Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. *Human Gene Therapy*, **2003**, 14, 1139-53	4.8	59
23	The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4. *Molecular Therapy*, **2002**, 5, 170-6	11.7	5
22	Retroviral delivery of connexin genes to human breast tumor cells inhibits in vivo tumor growth by a mechanism that is independent of significant gap junctional intercellular communication. *Journal of Biological Chemistry*, **2002**, 277, 29132-8	5.4	168
21	Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. *Gene Therapy*, **2002**, 9, 452-62	4	34
20	Green fluorescent protein in retroviral vector constructs as marker and reporter of gene expression for cell and gene therapy applications. *Methods in Molecular Biology*, **2002**, 183, 353-71	1.4	4
19	In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. *Cancer Research*, **2002**, 62, 5148-52	10.1	34
18	Disruption of NF-kappa B signaling and chemokine gene activation by retroviral mediated expression of IKK gamma/NEMO mutants. *Virology*, **2001**, 286, 422-33	3.6	5
17	Transcriptional regulation of the TFIIH transcription repair components XPB and XPD by the hepatitis B virus x protein in liver cells and transgenic liver tissue. *Journal of Biological Chemistry*, **2001**, 276, 14124-32	5.4	51
16	Parathyroid hormone-related protein promotes quiescence and survival of serum-deprived chondrocytes by inhibiting rRNA synthesis. *Journal of Biological Chemistry*, **2001**, 276, 37934-43	5.4	36
15	A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells. *Human Gene Therapy*, **2001**, 12, 1673-80	4.8	6

14	Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. *Human Gene Therapy*, **2001**, 12, 13-23	4.8	41
13	Inhibition of carcinoma cell growth and metastasis by a vesicular stomatitis virus G-pseudotyped retrovector expressing type I insulin-like growth factor receptor antisense. *Human Gene Therapy*, **2001**, 12, 1969-77	4.8	26
12	Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. *Journal of Thoracic and Cardiovascular Surgery*, **2000**, 120, 999-1005	1.5	327
11	Glucocorticoid-inducible retrovector for regulated transgene expression in genetically engineered bone marrow stromal cells. *Human Gene Therapy*, **2000**, 11, 1837-49	4.8	34
10	Neuronal differentiation and growth control of neuro-2a cells after retroviral gene delivery of connexin43. *Journal of Biological Chemistry*, **2000**, 275, 34407-14	5.4	60
9	Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. *Mutation Research DNA Repair*, **2000**, 460, 17-28		37
8	Effects of retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal and differentiation in culture. *Annals of the New York Academy of Sciences*, **1999**, 872, 125-40; discussion 140-1	6.5	26
7	Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. *Stem Cells*, **1998**, 16 Suppl 1, 223-33	5.8	15
6	In vivo selection of retrovirally transduced hematopoietic stem cells. *Nature Medicine*, **1998**, 4, 1136-43	50.5	191
5	Transduction of Murine Bone Marrow Cells With an MDR1 Vector Enables Ex Vivo Stem Cell Expansion, but These Expanded Grafts Cause a Myeloproliferative Syndrome in Transplanted Mice. *Blood*, **1998**, 92, 2269-2279	2.2	177
4	Transduction of Murine Bone Marrow Cells With an MDR1 Vector Enables Ex Vivo Stem Cell Expansion, but These Expanded Grafts Cause a Myeloproliferative Syndrome in Transplanted Mice. *Blood*, **1998**, 92, 2269-2279	2.2	10
3	Coding region-specific destabilization of mRNA transcripts attenuates expression from retroviral vectors containing class 1 aldehyde dehydrogenase cDNAs. *Human Gene Therapy*, **1997**, 8, 1531-43	4.8	7
2	A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs. *Human Gene Therapy*, **1997**, 8, 1773-83	4.8	47
1	Mesenchymal Stromal Cells as Effective Tumor Antigen-Presenting Cells in Cancer Therapeutics127-143		